Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 532-542

  Medina Caliz, Inmaculada ^a,b   Robles Diaz, Mercedes ^a,b   Garcia Muñoz, Beatriz ^a   Stephens, Camilla ^a,b   Ortega Alonso, Aida ^a   Garcia Cortes, Miren ^a,b   González Jimenez, Andres ^a   Sanabria Cabrera, Judith A ^a   Moreno, Inmaculada ^a,b   Fernandez, M Carmen ^c   Romero Gomez, Manuel ^b,d   Navarro, Jose M ^e   Barriocanal, Ana Mª ^f   Montane, Eva ^f   Hallal, Hacibe ^g   Blanco, Sonia ^h   Soriano, German ^b,i   Roman, Eva M ^b,i   Gómez Dominguez, Elena ^j   Castiella, Agustin ^k   Zapata, Eva M ^k   Jimenez Perez, Miguel ^l   Moreno, Jose M ^m   Aldea Perona, Ana ⁿ   Hernández Guerra, Manuel ⁿ   Prieto, Martin ^b,o   Zoubek, Miguel E ^a   Kaplowitz, Neil ^p   Lucena, M Isabel ^a,b   Andrade, Raul J ^a,b   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital de Torrecardenas   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL COSTA DEL SOL   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL MORALES MESEGUER   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k HOSPITAL DE MENDARO   (Spain)

^l HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^o HOSPITAL UNIVERSITARIO LA FE   (Spain)

^p UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

Chronic; Hepatotoxicity; Risk factors; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOTENSIN II ANTAGONIST; ANTIBIOTIC AGENT; BILIRUBIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CHRONICITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER CELL DAMAGE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; CHEMICAL AND DRUG INDUCED LIVER INJURY; FOLLOW-UP STUDIES; HUMANS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84979687048     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.003     Document Type: Article

References (47)

1. [1] Kaplowitz, N., Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4 (2005), 489–499.
2. [2] Lucena, M.I., Andrade, R.J., Kaplowitz, N., García-Cortes, M., Fernández, M.C., Romero-Gomez, M., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 49 (2009), 2001–2009.
3. [3] Kleiner, D.E., Chalasani, N.P., Lee, W.M., Fontana, R.J., Bonkovsky, H.L., Watkins, P.B., et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59 (2014), 661–670.
4. [4] Björnsson, E., Olsson, R., Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42 (2005), 481–489.
5. [5] Andrade, R.J., Lucena, M.I., Fernández, M.C., Pelaez, G., Pachkoria, K., García-Ruiz, E., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005), 512–521.
6. [6] Robles-Diaz, M., Lucena, M.I., Kaplowitz, N., Stephens, C., Medina-Cáliz, I., González-Jimenez, A., et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 147 (2014), 109–118.
7. [7] Chalasani, N., Fontana, R.J., Bonkovsky, H.L., Watkins, P.B., Davern, T., Serrano, J., et al. Causes, clinical features and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135 (2008), 1924–1934.
8. [8] Fontana, R.J., Hayashi, P.H., Gu, J., Reddy, K.R., Barnhart, H., Watkins, P.B., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147 (2014), 96–108.
9. [9] Seeff, L.B., Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis 1 (1981), 104–115.
10. [10] Aithal, P.G., Day, C.P., The natural history of histologically proved drug induced liver disease. Gut 44 (1999), 731–735.
11. [11] Björnsson, E., Davidsdottir, L., The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 50 (2009), 511–517.
12. [12] Benichou, C., Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 11 (1990), 272–276.
13. [13] Andrade, R.J., Lucena, M.I., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44 (2006), 1581–1588.
14. [14] Fontana, R.J., Watkins, P.B., Bonkovsky, H.L., Chalasani, N., Davern, T., Serrano, J., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 32 (2009), 55–68.
15. [15] Aithal, G.P., Watkins, P.B., Andrade, R.J., Larrey, D., Molokhia, M., Takikawa, H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89 (2011), 806–815.
16. [16] Fontana, R.J., Hayashi, P.H., Barnhart, H., Kleiner, D.E., Reddy, K.R., Chalasani, N., et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol 110 (2015), 1450–1459.
17. [17] Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001), 2486–2497.
18. [18] Word Health Organization Collaborating Center for drugs statistics methodology. Guidelines for Anatomical Therapeutic Chemical (ATC) classification and defined daily dose (DDD) assignment. 2014, World Health Organization Collaborating Center for Drug statistics methodology, Oslo, Norway.
19. [19] Danan, G., Benichou, C., Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46 (1993), 1323–1330.
20. [20] Björnsson, E., Kalaitzakis, E., Av Klinteberg, V., Alem, N., Olsson, R., Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 26 (2007), 79–85.
21. [21] Williams, C.D., Jaeschke, H., Role of innate and adaptive immunity during drug-induced liver injury. Toxicol Res 1 (2012), 161–170.
22. [22] Reuben, A., Koch, D.G., Lee, W.M., Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52 (2010), 2065–2076.
23. [23] Lucena, M.I., Kaplowitz, N., Hallal, H., Castiella, A., García-Bengoechea, M., Otazua, P., et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 55 (2011), 820–827.
24. [24] Andrade, R.J., Lucena, M.I., Martin-Vivaldi, R., Fernandez, M.C., Nogueras, F., Pelaez, G., et al. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol 31 (1999), 641–646.
25. [25] Pineda, J.A., Larrauri, J., Macías, J., Hernández, A., Guijarro, J., Sayago, M., et al. Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. J Hepatol 31 (1999), 777–778.
26. [26] Andrade, R.J., Lucena, M.I., Aguilar, J., Lazo, M.D., Camargo, R., Moreno, P., et al. Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Dig Dis Sci 45 (2000), 1400–1404.
27. [27] Perdices, E.V., Medina-Cáliz, I., Hernando, S., Ortega, A., Martín-Ocaña, F., Navarro, J.M., et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig 106 (2014), 246–254.
28. [28] Luparini, R.L., Rotundo, A., Mattace, R., Marigliano, V., Possibly ranitidine-induced autoimmune hepatitis. Ann Ital Med Int 15 (2000), 214–217.
29. [29] Black, M., Mitchell, J.R., Zimmerman, H.J., Ishak, K.G., Epler, G.R., Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69 (1975), 289–302.
30. [30] Sharp, J.R., Ishak, K.G., Zimmerman, H.J., Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 92 (1980), 14–19.
31. [31] Amit, G., Cohen, P., Ackerman, Z., Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 4 (2002), 184–186.
32. [32] Stricker, B.H., Blok, A.P., Claas, F.H., Van Parys, G.E., Desmet, V.J., Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8 (1988), 599–606.
33. [33] Olsson, R., Wiholm, B.E., Sand, C., Zettergren, L., Hultcrantz, R., Myrhed, M., Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 15 (1992), 154–161.
34. [34] Oikawa, H., Maesawa, C., Sato, R., Oikawa, K., Yamada, H., Oriso, S., et al. Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report. World J Gastroenterol 11 (2005), 5394–5397.
35. [35] Whiting-O'Keefe, Q.E., Fye, K.H., Sack, K.D., Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90 (1991), 711–716.
36. [36] Moradpour, D., Altorfer, J., Flury, R., Greminger, P., Meyenberger, C., Jost, R., et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 20 (1994), 1437–1441.
37. [37] Yeung, E., Wong, F.S., Wanless, I.R., Shiota, K., Guindi, M., Joshi, S., et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 127 (2003), 1493–1497.
38. [38] Mazeika, P.K., Ford, M.J., Chronic active hepatitis associated with diclofenac sodium therapy. Br J Clin Pract 43 (1989), 125–126.
39. [39] Clarke, A.T., Mills, P.R., Atorvastatin associated liver disease. Dig Liver Dis 38 (2006), 772–777.
40. [40] Russo, M.W., Hoofnagle, J.H., Gu, J., Fontana, R.J., Barnhart, H., Kleiner, D.E., et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 60 (2014), 679–686.
41. [41] Yao, F., Behling, C.A., Saab, S., Li, S., Hart, M., Lyche, K.D., Trimethoprim sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 92 (1997), 167–169.
42. [42] Kowdley, K.V., Keeffe, E.B., Fawaz, K.A., Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 102 (1992), 2148–2150.
43. [43] Chalasani, N., Bonkovsky, H.L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology, 148, 2015, e7.
44. [44] Chatrenet, P., Regimbeau, C., Ramain, J.P., Penot, J., Bruandet, P., Chronic active cirrhogenic hepatitis induced by fenofibrate. Gastroenterol Clin Biol 17 (1993), 612–613.
45. [45] Ghabril, M., Vuppalanchi, R., Drug-induced nodular regenerative hyperplasia. Semin Liver Dis 34 (2014), 240–245.
46. [46] Anania, F.A., Rabin, L., Terbinafine hepatotoxicity resulting in chronic biliaryductopenia and portal fibrosis. Am J Med 112 (2002), 741–742.
47. [47] Gendre, G., Buclin, T., Morard, I., Fontannaz, J., Berney, J.L., Terbinafine induced hepatitis with persistent cholestasis. Rev Med Suisse 4 (2008), 736–739.